{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000002","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.149129+00:00","generated_at":"2026-06-07T02:47:48.067617+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves Ligand's ZELSUVMI for molluscum contagiosum in adults and children 1+","bullets":["FDA approved ZELSUVMI (berdazimer topical gel, 10.3%) for molluscum contagiosum in patients 1 year and older.","First novel drug for molluscum and first topical prescription that can be applied at home.","Approximately 6 million Americans infected annually; up to 73% of children go untreated.","Product expected to be available in the U.S. in the second half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000002","json":"https://secwatch.observer/filing/0000886163-24-000002.json","markdown":"https://secwatch.observer/filing/0000886163-24-000002.md","text":"https://secwatch.observer/filing/0000886163-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000002/0000886163-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000002/lgnd-20240105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:47:48.067617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}